MX2020004443A - Tratamiento de la esquizofrenia. - Google Patents
Tratamiento de la esquizofrenia.Info
- Publication number
- MX2020004443A MX2020004443A MX2020004443A MX2020004443A MX2020004443A MX 2020004443 A MX2020004443 A MX 2020004443A MX 2020004443 A MX2020004443 A MX 2020004443A MX 2020004443 A MX2020004443 A MX 2020004443A MX 2020004443 A MX2020004443 A MX 2020004443A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- schizophrenia
- need
- treatment
- negative symptom
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title abstract 3
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010014557 Emotional poverty Diseases 0.000 abstract 1
- 206010016759 Flat affect Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un método para tratar la esquizofrenia en un sujeto que lo necesita, el método comprende administrar al sujeto una cantidad terapéuticamente efectiva de un antagonista selectivo de D3, en el que dicho sujeto tiene al menos un síntoma negativo (NS) entre los siguientes núcleos síntomas negativos en PANSS: Afecto plano (N1), Retracción emocional (N2), Mala relación (N3), Abstinencia pasiva (N4) y Falta de espontaneidad (N6); con severidad moderada o mayor. También se describen métodos para mejorar la probabilidad de éxito y/o el efecto de un tratamiento de esquizofrenia en un sujeto que lo necesite.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581249P | 2017-11-03 | 2017-11-03 | |
| PCT/EP2018/080154 WO2019086661A1 (en) | 2017-11-03 | 2018-11-05 | Treatment of schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004443A true MX2020004443A (es) | 2020-11-24 |
Family
ID=64402162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004443A MX2020004443A (es) | 2017-11-03 | 2018-11-05 | Tratamiento de la esquizofrenia. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10842789B2 (es) |
| EP (1) | EP3703695B1 (es) |
| JP (1) | JP7250787B2 (es) |
| KR (1) | KR20200083978A (es) |
| CN (1) | CN111295191A (es) |
| AU (1) | AU2018360298A1 (es) |
| BR (1) | BR112020007573A2 (es) |
| CA (1) | CA3079994A1 (es) |
| MA (1) | MA50511A (es) |
| MX (1) | MX2020004443A (es) |
| WO (1) | WO2019086661A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2663638B2 (fr) | 1990-04-06 | 1995-02-10 | Institut Nal Sante Recherc Medic | Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides. |
| FR2949465B1 (fr) * | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
-
2018
- 2018-11-05 MA MA050511A patent/MA50511A/fr unknown
- 2018-11-05 BR BR112020007573-6A patent/BR112020007573A2/pt not_active Application Discontinuation
- 2018-11-05 KR KR1020207011473A patent/KR20200083978A/ko not_active Application Discontinuation
- 2018-11-05 MX MX2020004443A patent/MX2020004443A/es unknown
- 2018-11-05 JP JP2020524639A patent/JP7250787B2/ja active Active
- 2018-11-05 CN CN201880070922.6A patent/CN111295191A/zh active Pending
- 2018-11-05 US US16/180,641 patent/US10842789B2/en active Active
- 2018-11-05 CA CA3079994A patent/CA3079994A1/en active Pending
- 2018-11-05 WO PCT/EP2018/080154 patent/WO2019086661A1/en unknown
- 2018-11-05 AU AU2018360298A patent/AU2018360298A1/en not_active Abandoned
- 2018-11-05 EP EP18806981.9A patent/EP3703695B1/en active Active
-
2020
- 2020-08-24 US US17/001,400 patent/US20200383976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190134026A1 (en) | 2019-05-09 |
| BR112020007573A2 (pt) | 2020-09-24 |
| EP3703695B1 (en) | 2022-12-21 |
| US20200383976A1 (en) | 2020-12-10 |
| JP7250787B2 (ja) | 2023-04-03 |
| WO2019086661A1 (en) | 2019-05-09 |
| AU2018360298A1 (en) | 2020-04-23 |
| JP2021501775A (ja) | 2021-01-21 |
| US10842789B2 (en) | 2020-11-24 |
| MA50511A (fr) | 2020-09-09 |
| KR20200083978A (ko) | 2020-07-09 |
| CN111295191A (zh) | 2020-06-16 |
| EP3703695A1 (en) | 2020-09-09 |
| CA3079994A1 (en) | 2019-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| CO2020016559A2 (es) | Anticuerpos que se dirigen al gp120 de vih y métodos de uso | |
| PE20201177A1 (es) | Tarjeta de transaccion con componentes electronicos incorporados y procedimiento para su fabricacion | |
| CL2018000684A1 (es) | Moduladores de la proteína de núcleo de la hepatitis b. | |
| CO2017010583A2 (es) | Compuestos de pirazol y método para elaborar y usar los compuestos | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CO2017005034A2 (es) | Tratamiento de convulsiones con fosfatasa alcalina recombinante | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CL2020002774A1 (es) | Tratamiento combinado de fibrosis y/o angiogénesis ocular | |
| CR20190162A (es) | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado | |
| BR112018069717A2 (pt) | montagem de cateter urinário, cateter urinário, e, método de remoção de um cateter de uma montagem de cateter. | |
| CL2018001258A1 (es) | Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2 | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| PE20120998A1 (es) | Metodos para el tratamiento del cancer usando antagonistas de notch | |
| CL2018000377A1 (es) | Mecanismo de resistencia a inhibidores de bromodominio bet | |
| UY38075A (es) | Composiciones anticonceptivas con efectos cardiovasculares reducidos | |
| CO2017013275A2 (es) | Índice de búsqueda personal con privacidad mejorada" | |
| CO2019007906A2 (es) | Inhibidores de poli-adp ribosa polimerasa (parp) | |
| CL2018001304A1 (es) | Método de protección eficiente del lsp basado en el túnel dinámico rsvp-te | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| CR20110184A (es) | Inhibidores de la integrasa del vih | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 |